Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Oncolytics Biotech Announces 2017 First Quarter Results May 4, 2017 Caribou Biosciences Appoints Ph.D. As Chief Scientific Officer July 5, 2017 Officials Eye New Biotech Tenants for Bristol-Myers' Former Connecticut Complex February 15, 2018
